Michael Nally, Generate Biomedicines CEO

MD An­der­son, Flag­ship start­up part­ner to de­sign and test can­cer drugs made with gen­er­a­tive AI

Gen­er­ate Bio­med­i­cines, a start­up found­ed by the life sci­ence in­vest­ment com­pa­ny Flag­ship Pi­o­neer­ing, has part­nered with the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter to de­vel­op pro­tein ther­a­pies made from gen­er­a­tive AI, the ar­ti­fi­cial in­tel­li­gence tech­nique that’s sweep­ing the web with text gen­er­a­tors such as Chat­G­PT and im­age gen­er­a­tors like DALL-E.

The col­lab­o­ra­tion, an­nounced Thurs­day morn­ing, will span the gamut of drug dis­cov­ery and de­vel­op­ment. The pair will ini­tial­ly iden­ti­fy up to five tar­gets in ad­vanced can­cers, in­clud­ing lung can­cer, to de­sign drugs for Gen­er­ate’s com­pu­ta­tion­al and wet labs in Somerville, MA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.